<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01149018</url>
  </required_header>
  <id_info>
    <org_study_id>THC-FMS-HMO-CTIL</org_study_id>
    <nct_id>NCT01149018</nct_id>
  </id_info>
  <brief_title>Efficacy Trial of Oral Tetrahydrocannabinol in Patients With Fibromyalgia</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Trial of Oral Tetrahydrocannabinol (âˆ†-9-THC) in Patients With Fibromyalgia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hebrew University of Jerusalem</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to evaluate the effectiveness of oral tetrahydrocannabinol in
      patients suffering from Fibromyalgia
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2010</start_date>
  <completion_date type="Anticipated">October 2012</completion_date>
  <primary_completion_date type="Anticipated">July 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Meaningful change in Total score on Fibromyalgia Impact Questionnaire (FIQ)</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Meaningful change in Brief Pain Inventory average pain severity.</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Fibromyalgia</condition>
  <arm_group>
    <arm_group_label>Tetrahydrocannabinol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tetrahydrocannabinol</intervention_name>
    <description>Oral solution of THC in concentration of 5mg/0.2ml. Dose regimen: 5mg 2-4 times/day as tolerated.</description>
    <arm_group_label>Tetrahydrocannabinol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Orally administered olive oil. Dose: 0.2ml 2-4 times a day as tolerated</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Adult (&gt;18y.o) Patient with Fibromyalgia, diagnosed by ACR criteria

        Exclusion Criteria:

        - Children &lt; 18 years old

        Patients with following psychiatric disorders:

          -  Psychosis or history of acute psychosis

          -  Schizophrenia

          -  Bipolar disorder Patients smoking marijuana, using hashish or any other form of
             cannabis. Patients with history of drug abuse or illicit drug use Patients receiving
             chronic treatment with strong opioids (Morphine, Oxycodone, Fentanyl, Methadone,
             Hydromorphone, Buprenorphine, Pethidine). Weak opioids as Tramadol or Propoxyphene
             will be allowed.

        Pregnant patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Elyad Davidson, MD</last_name>
    <phone>+972 2677 6911</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Simon Haroutiunian, M.Sc</last_name>
    <phone>+972 2677 6770</phone>
    <email>simonh@ekmd.huji.ac.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Pain Relief Unit, Hadassah Medical Organisation</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2010</study_first_submitted>
  <study_first_submitted_qc>June 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2010</study_first_posted>
  <last_update_submitted>June 22, 2010</last_update_submitted>
  <last_update_submitted_qc>June 22, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2010</last_update_posted>
  <responsible_party>
    <name_title>Elyad Davidson, MD</name_title>
    <organization>Hadassah Medical Organization</organization>
  </responsible_party>
  <keyword>Fibromyalgia</keyword>
  <keyword>Tetrahydrocannabinol</keyword>
  <keyword>Chronic Widespread Pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dronabinol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

